Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With Anlotinib and Nab-paclitaxel in Patients With Untreated Advanced Mucosal Melanoma:a Single-arm, Multicenter, Open-label Study

NCT04979585 is registered in ClinicalTrials.gov with Di Wu as lead sponsor.

NCT NCT04979585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04979585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With Anlotinib and Nab-paclitaxel in Patients With Untreated Advanced Mucosal Melanoma:a Single-arm, Multicenter, Open-label Study
Lead sponsor
Di Wu
Phase
Phase 2
Overall status
Unknown status
Start date
July 15, 2021
Completion date
August 14, 2023
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma